Luca Costantino

List of Publications by Year in Descending Order

85 papers	3,751 citations	32 h-index	59 g-index
91 ext. papers	4,056 ext. citations	5.8 avg, IF	5.1 L-index

#	Paper	IF	Citations
85	In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?. *Nanomaterials*, **2020**, 10,	5.4	21
84	New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 823-828	5.6	14
83	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections. *Journal of Medicinal Chemistry*, **2019**, 62, 3989-4012	8.3	11
82	Teaching an Undergraduate Organic Chemistry Laboratory Course with a Tailored Problem-Based Learning Approach. *Journal of Chemical Education*, **2019**, 96, 888-894	2.4	11
81	The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant. *Pharmaceutics*, **2019**, 11,	6.4	13
80	An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis. *Current Topics in Medicinal Chemistry*, **2019**, 19, 646-661	3	15
79	Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy. *Drug Delivery and Translational Research*, **2019**, 9, 298-310	6.2	25
78	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. *European Journal of Medicinal Chemistry*, **2018**, 146, 423-434	6.8	19
77	New Chromane-Based Derivatives as Inhibitors of Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies. *Molecules*, **2018**, 23,	4.8	21
76	Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents. *European Journal of Medicinal Chemistry*, **2018**, 155, 754-763	6.8	38
75	Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors. *Medicinal Chemistry Research*, **2017**, 26, 975-986	2.2	9
74	Surface engineering of Solid Lipid Nanoparticle assemblies by methyl α-d-mannopyranoside for the active targeting to macrophages in anti-tuberculosis inhalation therapy. *International Journal of Pharmaceutics*, **2017**, 528, 440-451	6.5	33
73	Methoxylated 2′-hydroxychalcones as antiparasitic hit compounds. *European Journal of Medicinal Chemistry*, **2017**, 126, 1129-1135	6.8	17
72	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Pteridine Reductase in Support of Early-Stage Drug Discovery. *ACS Omega*, **2017**, 2, 5666-5683	3.9	17
71	Folate: Relevance of Chemical and Microbial Production **2016**, 103-128		6
70	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. *Journal of Medicinal Chemistry*, **2016**, 59, 7598-616	8.3	30
69	Iron Acquisition Pathways as Targets for Antitubercular Drugs. *Current Medicinal Chemistry*, **2016**, 23, 4009-4026	4.3	27

68	New perspectives on the development of antiobesity drugs. *Future Medicinal Chemistry*, **2015**, 7, 315-36	4.1	4
67	Ghrelin receptor modulators: a patent review (2011 - 2014). *Expert Opinion on Therapeutic Patents*, **2014**, 24, 1007-19	6.8	8
66	Challenges in the design of clinically useful brain-targeted drug nanocarriers. *Current Medicinal Chemistry*, **2014**, 21, 4227-46	4.3	7
65	Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. *Current Medicinal Chemistry*, **2014**, 21, 4247-56	4.3	42
64	2′Deoxyuridine 5′monophosphate substrate displacement in thymidylate synthase through 6-hydroxy-2H-naphtho[1,8-bc]furan-2-one derivatives. *Journal of Medicinal Chemistry*, **2013**, 56, 9356-60	8.3	6
63	Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?. *Drug Discovery Today*, **2012**, 17, 367-78	8.8	76
62	Magnetic and optical bistability in tetrairon(III) single molecule magnets functionalized with azobenzene groups. *Dalton Transactions*, **2012**, 41, 8368-78	4.3	22
61	Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. *Nanomedicine*, **2012**, 7, 121-31	5.6	87
60	Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (WO2012035124): a patent evaluation. *Expert Opinion on Therapeutic Patents*, **2012**, 22, 1099-104	6.8	1
59	Designed multiple ligands: basic research vs clinical outcomes. *Current Medicinal Chemistry*, **2012**, 19, 3353-87	4.3	47
58	Growth hormone secretagogue receptor antagonists. *Expert Opinion on Therapeutic Patents*, **2012**, 22, 697-700	6.8	5
57	Drug delivery to the CNS and polymeric nanoparticulate carriers. *Future Medicinal Chemistry*, **2010**, 2, 1681-701	4.1	13
56	Methods for synthesis and uses of inhibitors of ghrelin O-acyltransferase inhibitors as potential therapeutic agents for obesity and diabetes. *Expert Opinion on Therapeutic Patents*, **2010**, 20, 1603-7	6.8	2
55	Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. *Journal of Controlled Release*, **2010**, 145, 49-57	11.7	96
54	PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. *Biomaterials*, **2010**, 31, 3395-403	15.6	56
53	Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2009**, 5, 369-77	6	110
52	Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 2658-72	3.4	35
51	Chapter 3 - Colloidal systems for CNS drug delivery. *Progress in Brain Research*, **2009**, 180, 35-69	2.9	23

50	AFM phase imaging of soft-hydrated samples: a versatile tool to complete the chemical-physical study of liposomes. *Journal of Liposome Research*, **2009**, 19, 59-67	6.1	24
49	Ghrelin receptor modulators and their therapeutic potential. *Future Medicinal Chemistry*, **2009**, 1, 157-77	4.1	12
48	Polymeric nanoparticles for the drug delivery to the central nervous system. *Expert Opinion on Drug Delivery*, **2008**, 5, 155-74	8	161
47	STAT 3 as a target for cancer drug discovery. *Current Medicinal Chemistry*, **2008**, 15, 834-43	4.3	81
46	Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. *Journal of Controlled Release*, **2007**, 122, 1-9	11.7	187
45	Privileged Structures as Leads in Medicinal Chemistry. *Current Medicinal Chemistry*, **2006**, 13, 65-85	4.3	295
44	Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures. *Biomaterials*, **2006**, 27, 4635-45	15.6	64
43	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. *Journal of Medicinal Chemistry*, **2005**, 48, 266-73	8.3	20
42	Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. *Journal of Controlled Release*, **2005**, 108, 84-96	11.7	184
41	Synthesis of novel benzoic acid derivatives with benzothiazolyl subunit and evaluation as aldose reductase inhibitors. *Archiv Der Pharmazie*, **2005**, 338, 411-8	4.3	15
40	Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives. *European Journal of Pharmaceutical Sciences*, **2004**, 21, 545-52	5.1	12
39	Soft docking and multiple receptor conformations in virtual screening. *Journal of Medicinal Chemistry*, **2004**, 47, 5076-84	8.3	199
38	Inhibitors for proteins endowed with catalytic and non-catalytic activity which recognize pTyr. *Current Medicinal Chemistry*, **2004**, 11, 2725-47	4.3	15
37	Isolation and pharmacological activities of the Tecoma stans alkaloids. *Il Farmaco*, **2003**, 58, 781-5		39
36	On the prodrug potential of novel aldose reductase inhibitors with diphenylmethyleneaminooxycarboxylic acid structure. *European Journal of Pharmaceutical Sciences*, **2002**, 15, 11-20	5.1	8
35	Binding of 1-benzopyran-4-one derivatives to aldose reductase: a free energy perturbation study. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 1427-36	3.4	8
34	Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 1077-84	3.4	188
33	Discovery of new inhibitors of aldose reductase from molecular docking and database screening. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 1437-50	3.4	52

32	Nitrophenyl derivatives as aldose reductase inhibitors. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 3923-31	3.4	20
31	Oxidative modification of aldose reductase induced by copper ion. Definition of the metal-protein interaction mechanism. *Journal of Biological Chemistry*, **2002**, 277, 42017-27	5.4	51
30	7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: a SAR study. *European Journal of Medicinal Chemistry*, **2001**, 36, 697-703	6.8	18
29	A series of diarylsubstituted oximes as potential substrate for new aldose reductase inhibitors. *Journal of Heterocyclic Chemistry*, **2000**, 37, 1089-1096	1.9	7
28	Structural bases for the inhibition of aldose reductase by phenolic compounds. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 1151-8	3.4	30
27	Synthesis and aldose reductase inhibitory activity of a new series of benz[h]cinnolinone derivatives. *Il Farmaco*, **2000**, 55, 544-52		17
26	Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH. *Experimental Eye Research*, **2000**, 71, 515-21	3.7	30
25	Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. *Drug and Alcohol Dependence*, **2000**, 60, 121-32	4.9	153
24	Pharmacological approaches to the treatment of diabetic complications. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 1245-1262	6.8	65
23	Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. *Medicinal Research Reviews*, **1999**, 19, 3-23	14.4	133
22	1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. *Journal of Medicinal Chemistry*, **1999**, 42, 1881-93	8.3	82
21	Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. *Journal of Medicinal Chemistry*, **1999**, 42, 1894-900	8.3	30
20	Free energy perturbation studies on binding of the inhibitor 5,6-dihydrobenzo[h]cinnolin-3(2H)one-2-acetic acid and its methoxylated analogs to aldose reductase. *Tetrahedron*, **1998**, 54, 9415-9428	2.4	11
19	Synthesis and aldose reductase inhibitory activity of benzoyl-amino acid derivatives. *Il Farmaco*, **1998**, 53, 439-42		5
18	Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 641-6	2.9	16
17	Synthesis and activity of a new series of chalcones as aldose reductase inhibitors. *European Journal of Medicinal Chemistry*, **1998**, 33, 859-866	6.8	43
16	Oxidative modification of aldose reductase induced by copper ion. Factors and conditions affecting the process. *Biochemistry*, **1998**, 37, 14167-74	3.2	18
15	New aldose reductase inhibitors as potential agents for the prevention of long-term diabetic complications. *Expert Opinion on Therapeutic Patents*, **1997**, 7, 843-858	6.8	55

14	A Model of the Interaction of Substrates and Inhibitors with Xanthine Oxidase. *Journal of the American Chemical Society*, **1997**, 119, 3007-3016	16.4	33
13	Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase. *Bioorganic and Medicinal Chemistry Letters*, **1997**, 7, 1897-1902	2.9	24
12	Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase. *Journal of Medicinal Chemistry*, **1996**, 39, 2529-35	8.3	32
11	Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. *Journal of Medicinal Chemistry*, **1996**, 39, 4396-405	8.3	85
10	A rational approach to the design of flavones as xanthine oxidase inhibitors. *European Journal of Medicinal Chemistry*, **1996**, 31, 693-699	6.8	34
9	Theoretical and experimental study of flavones as inhibitors of xanthine oxidase. *European Journal of Medicinal Chemistry*, **1995**, 30, 141-146	6.8	16
8	Inhibition of lens aldose reductase by biflavones from Ouratea spectabilis. *Planta Medica*, **1995**, 61, 217-20	3.1	24
7	Quantitative measurement of proton dissociation and tautomeric constants of apigeninidin. *Journal of the Chemical Society Perkin Transactions II*, **1995**, 227		6
6	Solvent effects on the tautomerism of apigeninidin. *Tetrahedron Letters*, **1994**, 35, 9751-9754	2	1
5	Anti-inflammatory activity of newly synthesized 2,6-bis-(1,1-dimethylethyl)phenol derivatives. *Pharmacological Research*, **1993**, 27, 349-58	10.2	11
4	Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. *Planta Medica*, **1992**, 58, 342-4	3.1	137
3	Inhibitory activity of flavonols towards the xanthine oxidase enzyme. *International Journal of Pharmaceutics*, **1992**, 86, 17-23	6.5	11
2	Determination of drug-macromolecule binding parameters by numerical analysis. *Analytica Chimica Acta*, **1991**, 244, 145-149	6.6	
1	Heteroarylalkanoic acids with possible antiinflammatory activities, III. *Archiv Der Pharmazie*, **1985**, 318, 903-11	4.3	3